PsychedelicNewsBreaks

TuesdayFeb 16, 2021 12:07 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Enters Licensing Deal with Taste-T LLC

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, has announced its licensing deal with U.S. based Taste-T LLC. According to the update, Taste-T utilizes a proprietary manufacturing system to produce and package branded cannabis gummies and sells them in multiple U.S. states including Nevada, Massachusetts, Michigan and Oklahoma. Their famous products come in unique blister packaging and include Margarita Chill and Fireball Cinnamon. Pure Extracts has signed an agreement with exclusive rights for Canada and first rights to other countries around the world. Included…

Continue Reading

WednesdayFeb 10, 2021 10:14 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Studying Potential for Psychedelics in Treatment of Mental Health Conditions, Announces Addition of Mescaline to Subsidiary Medicine Programs

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline to its psychedelic medicine programs. These psychedelic compounds show promising potential in treating mental conditions because they are known to modulate neurotransmitters such as serotonin and dopamine, which regulate cognition, perception and mood in individuals. Called a leader in innovating psychedelic drugs in a recent…

Continue Reading

WednesdayFeb 10, 2021 10:04 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Announces First Commercial Contract for CBD Oil

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has contracted for its initial commercial CBD oil sale. The company anticipated the contract will result in multiple shipments of its 85% pure CBD distillate offering this year. Pure Extracts’ state-of-the-art, subcritical/super-critical CO2 extraction system produces an exceptionally pure THC and CBD full-spectrum oil and distillate. The resulting distillate can be used to manufacture a variety of cannabis 2.0 products, such as beverages, edibles and vape pens. The announcement also noted that Pure Extracts continues its commitment to increase awareness.…

Continue Reading

FridayFeb 05, 2021 3:04 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Positioned Amid Growing Acceptance, Legalization of Psilocybin

Cybin (NEO: CYBN) is a mushroom life science company focused on the pharmaceutical development of psychedelic products. Cybin’s subsidiary Serenity Life Sciences is engaged in the research and development of psilocybin-based medications. Widely referred to as magic mushrooms, Psilocybin has had its share of bad press. However, the company is positioned as perceptions of this substance are beginning to change. A recent article discussing this reads, “Under the Controlled Substances Act, psilocybin is included with heroin and LSD as a Schedule I drug. According to the National Drug Intelligence Center, psilocybin serves no legitimate medical purpose in the United States.…

Continue Reading

WednesdayFeb 03, 2021 11:48 am

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Publication of Article Led by CEO Dr. Roger McIntyre

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by its CEO Dr. Roger McIntyre. The article, titled, “The Rapid Mood Screener (‘RMS’): a novel and pragmatic screener for bipolar I disorder,” is published at Taylor and Francis.com. "Timely and accurate diagnoses are precursors of good clinical outcomes in persons with treatment-resistant mood disorders, the high rate of missed bipolar disorder diagnosis is a critical unmet need," stated Dr. Roger McIntyre. "The Rapid Mood Screener provides a systematic approach to screening for bipolar disorder amongst all patients who present with depressive symptoms. It…

Continue Reading

WednesdayFeb 03, 2021 11:06 am

PsychedelicNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis of pharmaceutical-grade psychedelic compounds and the development of the standard operating procedures required to obtain regulatory approval for the commercial production process. As part of its psychedelic pharmaceutical program, XPhyto needs industrial-scale production of standardized active pharmaceutical ingredients. This agreement is part of that strategic…

Continue Reading

WednesdayFeb 03, 2021 10:39 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Completes New Company Registration for Class 1 NPN

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company specializing in cannabis, hemp and mushroom products, announced that it has completed its application for new company registration with the Natural and Non-prescription Health Products Directorate (“NNHPD”) and subsequently has received its company code. As a result, Pure Extracts can now submit an application for a Class 1 Natural Product Number (“NPN”) for a functional mushroom product. PULL anticipates this will be the first of several NPN applications it submits in 2021. The applications are part of Pure Extracts strategic plan to sell functional mushroom wellness products through…

Continue Reading

FridayJan 29, 2021 2:55 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) Poised to Provide Breakthrough Therapy for MDD

Cybin (NEO: CYBN), a mushroom life science company, is at the forefront of new treatments targeting major depressive disorder (“MDD”). The company is working to become the first to bring a psilocybin drug to market that targets MDD. This positions Cybin to provide solutions amid significant demand, with more than 18 million people in the United States and 300 million people worldwide who experience major depression according to the National Institute of Mental Health. A recent article discussing this reads, “Since 2018, the FDA has labeled psychedelic psilocybin a ‘breakthrough therapy’ to treat MDD. This designation fast tracks the substance…

Continue Reading

WednesdayJan 27, 2021 1:52 pm

PsychedelicNewsBreaks – Pure Extracts Technologies Corp.’s (CSE: PULL) (OTC: PRXTF) US Shares Gain DTC Eligibility

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, this morning announced that its common shares on the OTC Market under the symbol "PRXTF" are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC"). “DTC eligibility is a major step forward in increasing liquidity, broadening our shareholder base and building a strong presence for our company within the US capital markets sphere. This is an important step in amplifying our story to a wider audience,” Pure Extracts CEO Ben Nikolaevsky stated in the news release. To view…

Continue Reading

TuesdayJan 26, 2021 10:27 am

PsychedelicNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) Announces Biomass Purchase Agreements to Scale-Up Extract Production

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has entered into its first initial substantial biomass purchase agreements; the agreements are designed to support an increase in the company’s production of THC and CBD oil extracts. Executed with a large Canadian Licensed Producer, one purchase agreement outlines Pure Extracts’ intent to purchase 220 kgs of high-potency THC cannabis dried flower; the company also agreed to purchase approximately 1,000 kgs of high-potency CBD biomass from a top Western Canada cultivator. The company plans to use the cannabis to produce full-spectrum (“FSO”) THC…

Continue Reading